ERBB2 and breast carcinoma: In a retrospectively evaluated population of 100 HER2 positive, early and locally advanced breast cancer women treated with trastuzumab in the adjuvant setting, 38% of the patients exhibited cardiotoxicity and nearly 23% required discontinuation of the medication due to cardiac complications.